$0.71
(Market cap
$276,380 Mln
Recently Viewed
Clear AllMarket cap
$276,380 Mln
Revenue (TTM)
$65,011 Mln
P/E Ratio
15.4
P/B Ratio
5.4
Div. Yield
2.8 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$18,254 Mln
ROE
0.4 %
ROCE
19.4 %
Industry P/E
--
EV/EBITDA
11.2
Debt to Equity
1
Book Value
$21.1
EPS
$7.3
Face value
--
Shares outstanding
2,469,879,206
CFO
$117,929.00 Mln
EBITDA
$115,983.00 Mln
Net Profit
$75,684.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Merck & Company Inc (MRK)
| 6.1 | -6.7 | 4.5 | 31.8 | -1.1 | 9.7 | 7.9 |
|
BSE Sensex
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P 100
| 2.0 | 13.9 | 2.3 | 31.7 | 22.6 | 13.2 | 14.4 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Merck & Company Inc (MRK)
| 5.8 | -8.7 | -1.7 | 44.8 | 1.9 | -7.1 | 22.4 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Merck & Company Inc (MRK)
|
111.7 | 276,379.5 | 65,011.0 | 18,254.0 | 33.9 | 36.9 | 15.4 | 5.4 |
| 214.1 | 355,432.8 | 61,160.0 | 4,226.0 | 15.5 | 15367.3 | 84.8 | 50.5 | |
| 348.5 | 185,735.8 | 36,741.0 | 7,711.0 | 36.8 | 106.1 | 24.2 | 21.7 | |
| 60.1 | 119,870.3 | 48,194.0 | 7,053.0 | 22.2 | 40.5 | 17.1 | 6.5 | |
| 926.9 | 789,692.3 | 65,179.0 | 20,638.3 | 40.5 | 101.3 | 38.5 | 30.9 | |
| 131.9 | 161,853.0 | 29,443.0 | 8,510.0 | 28.8 | 40.6 | 19.2 | 7.3 | |
| 230.6 | 555,224.5 | 96,362.0 | 21,040.0 | 20.2 | 26.2 | 26.7 | 6.8 | |
| 148.0 | 284,672.3 | 54,811.3 | 14,055.6 | 31.2 | 31.2 | 20.6 | 6.1 | |
| 26.9 | 151,708.5 | 62,579.0 | 7,770.0 | 16.3 | 8.9 | 19.6 | 1.8 | |
| 46.7 | 112,077.9 | 47,354.0 | 7,555.0 | 19.6 | 10.3 | 20.2 | 1.3 |
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23,... Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey. Read more
Chairman, President & CEO
Mr. Robert M. Davis J.D.
Chairman, President & CEO
Mr. Robert M. Davis J.D.
Headquarters
Rahway, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Merck & Company Inc (MRK) is $111.66 (NYSE) as of 30-Apr-2026 10:47 EDT. Merck & Company Inc (MRK) has given a return of -1.11% in the last 3 years.
The P/E ratio of Merck & Company Inc (MRK) is 15.37 times as on 24-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
14.35
|
4.98
|
|
2024
|
14.77
|
5.46
|
|
2023
|
762.89
|
7.41
|
|
2022
|
19.47
|
6.15
|
|
2021
|
14.89
|
5.09
|
The 52-week high and low of Merck & Company Inc (MRK) are Rs 125.14 and Rs 73.31 as of 30-Apr-2026.
Merck & Company Inc (MRK) has a market capitalisation of $ 276,380 Mln as on 24-Apr-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Merck & Company Inc (MRK), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.